Literature DB >> 17162222

Molecular and structural basis of portal hypertension.

Richard Moreau1, Didier Lebrec.   

Abstract

Portal hypertension is a complication of diseases that obstruct portal blood flow, such as cirrhosis or portal vein thrombosis. In these diseases, increased vascular resistance to portal blood flow is the primary mechanism that increases portal pressure. In cirrhosis, increased intrahepatic vascular resistance is a result of both intrahepatic vasoconstriction and surrounding mechanical factors including collagen deposition and regenerative nodules. This article summarizes recent progress in the understanding of molecular mechanisms underlying the portal hypertension-associated arterial alterations in splanchnic systemic territories and those involved in the development of portal-systemic collateral circulation.

Entities:  

Mesh:

Year:  2006        PMID: 17162222     DOI: 10.1016/j.cld.2006.08.011

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  11 in total

Review 1.  Vascular smooth muscle phenotypic diversity and function.

Authors:  Steven A Fisher
Journal:  Physiol Genomics       Date:  2010-08-24       Impact factor: 3.107

2.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

3.  Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.

Authors:  Sonam Vadera; Charles Wei Kit Yong; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-20

4.  Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis.

Authors:  Jian Liang; Xin Deng; Zhi-Xiu Lin; Li-Chun Zhao; Xi-Liu Zhang
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

Review 5.  Splanchnic-aortic inflammatory axis in experimental portal hypertension.

Authors:  Maria-Angeles Aller; Natalia de las Heras; Maria-Paz Nava; Javier Regadera; Jaime Arias; Vicente Lahera
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

6.  Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation.

Authors:  Barbara Renga; Andrea Mencarelli; Marco Migliorati; Eleonora Distrutti; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

Review 7.  Inflammation: a way to understanding the evolution of portal hypertension.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Arturo Cruz; Jaime Arias
Journal:  Theor Biol Med Model       Date:  2007-11-13       Impact factor: 2.432

Review 8.  Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.

Authors:  Antony P Zacharias; Rebecca Jeyaraj; Lise Hobolth; Flemming Bendtsen; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29

9.  Chronic prehepatic portal hypertension in the rat: is it a type of metabolic inflammatory syndrome?

Authors:  Fernando Sánchez-Patán; Raquel Anchuelo; Maria-Angeles Aller; Elena Vara; Cruz García; Maria-Paz Nava; Jaime Arias
Journal:  Lipids Health Dis       Date:  2008-02-13       Impact factor: 3.876

Review 10.  The mast cell integrates the splanchnic and systemic inflammatory response in portal hypertension.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Jaime Arias
Journal:  J Transl Med       Date:  2007-09-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.